Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

NCT01241708 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT01241708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01241708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Lead sponsor
Hackensack Meridian Health
Phase
Phase 3
Overall status
Completed
Start date
April 8, 2010
Completion date
July 15, 2023
Enrollment
148 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

auto stem cell transplant, multiple myeloma